Skip to main content

Table 1 Clinical features of patients

From: Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study

Items

Erlotinib Group (N = 108)

Gefinitib Group (N = 171)

P value

Age, y (%)

0.719

  ≥ 60

45 (41.7%)

75 (43.9%)

 

  < 60

63 (58.3%)

96 (56.1%)

 

Gender, n (%)

0.343

 Male

53 (49.1%)

74 (43.3%)

 

 Female

55 (50.9%)

97 (56.7%)

 

Smoking history a, n (%)

  

0.359

 Never smoking

70 (64.8%)

120 (70.2%)

 

 Now/once smoking

38 (35.2%)

51 (29.8%)

 

ECOG PS score, n (%)

0.491

 0-1

106 (98.1%)

165 (96.5%)

 

 2

2 (1.9%)

6 (3.5%)

 

Pathological type, n (%)

1.000

 Adenocarcinoma

98 (90.7%)

156 (91.2%)

 

 Non adenocarcinoma

10 (9.3%)

15 (8.8%)

 

Cancer stagingb, n (%)

0.088

 Recurrent type c

18 (16.7%)

44 (25.7%)

 

 IIIb stage

7 (6.5%)

17 (9.9%)

 

IV stage

83 (76.9%)

110 (64.3%)

 

Cerebral metastasis before EGFR-TKIs use, n (%)

24 (22.2%)

22 (12.9%)

0.047

Previous treatment of cerebral metastasis, No.

 WBRT + TKI

14

11

 

 Surgery + WBRT

2

3 (1)

 

 WBRT + SRS

4

5

 

 None

4

3

 

Cerebral metastasis number before EGFR-TKIs use, n

 1

2

3

 

 2-3

4

5

 

  ≥ 4

18

14

 
  1. a Present smoker was defined as someone who had smoked more than 100 cigarettes in their lifetime but either currently being smoking or stopped smoking less than 1 year ago; former smoker was defined as someone who had smoked more than 100 cigarettes in their lifetime and stopped smoking at least 1 year ago; non-smoker was defined as having either smoked 100 or fewer cigarettes in their lifetime or had never smoked cigarettes
  2. b American Joint Committee on Cancer staging system 7th edition
  3. c Patients with stage I-IIIa NSCLC with systemic recurrence following definitive therapy that included surgical resection or radiotherapy